传统与改良Harborview风险评分对破裂性腹主动脉瘤30天死亡预测的外部验证
该研究回顾性纳入2012年1月至2024年1月在一家三级血管外科中心连续接受破裂性腹主动脉瘤修复的105例患者,外部验证传统与改良Harborview风险评分(tHRS、mHRS)对30天死亡的预测能力。tHRS的AUC为0.56,mHRS的AUC为0.68,校准显示对30天死亡存在高估;作者认为两评分预测能力有限,应考虑因素间交互作用以提升评分表现。
要点
- 105例破裂性腹主动脉瘤患者中,30天死亡率为31.4%(33/105)。
- tHRS的AUC为0.56,mHRS的AUC为0.68,DeLong检验P=0.29。
- tHRS对预测死亡率<25%者低估、其余高估;mHRS对估计死亡率<40%者校准良好、之后高估。
核心结论
- tHRS与mHRS在外部验证中预测能力有限,对30天死亡存在高估,作者对其广泛和系统应用提出诸多担忧。
- 作者认为应考虑因素间交互作用以提升评分表现,尤其在高风险患者中。
研究设计与样本
- 回顾性连续纳入2012年1月至2024年1月在一家三级血管外科中心接受破裂性腹主动脉瘤修复的患者。
- 共纳入105例患者(97例男性,92.4%),年龄77±8.5岁。
- 35例接受腔内修复(rEVAR,3例女性,80±9.0岁),70例接受开放修复(rOAR,5例女性,75±8.0岁)。
- 计算每例患者的tHRS与mHRS,构建ROC曲线、AUC(95%CI)及校准图评估区分度与校准度;并行多因素logistic模型更新死亡与评分变量的关系,应用于一千次bootstrap样本。
主要发现
- 30天死亡率总体为31.4%(33/105),rEVAR为25.7%(9/35),rOAR为34.3%(24/70),P=0.5。
- 入院时8例(7.6%)正在接受华法林治疗。
- tHRS的AUC为0.56,mHRS的AUC为0.68,DeLong检验P=0.29。
- tHRS校准显示对预测死亡率<25%的患者低估、对其余患者高估;mHRS对估计死亡率<40%的患者预测校准良好、之后高估。
- 模型更新显示更广泛的影响源于HRS各因素间的交互作用。
关键数值与推荐
- tHRS的AUC为0.56,mHRS的AUC为0.68(DeLong检验P=0.29)。
- tHRS对预测死亡率<25%者低估、其余高估;mHRS对估计死亡率<40%者校准良好、之后高估。
- 30天死亡率:总体31.4%(33/105),rEVAR 25.7%(9/35),rOAR 34.3%(24/70),P=0.5。
临床怎么用
- 作者认为tHRS与mHRS预测能力有限且存在30天死亡高估,对其广泛和系统应用提出诸多担忧。
- 作者认为应考虑因素间交互作用以提升评分表现,尤其在高风险患者中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A critical issue in the preoperative assessment of a patient with a ruptured abdominal aortic aneurysm (rAAA) is death risk prediction. The traditional and modified Harborview Risk Score (tHRS and mHRS) consider readily available variables to estimate 30-day mortality. The aim of the study was to validate tHRS and mHRS in a rAAA external population. METHODS: Consecutive patients undergoing rAAA repair from January 2012 to January 2024 at a tertiary Vascular Surgery Center were retrospectively reviewed. The scores were calculated for each patient; receiver operating characteristic curves (ROC), area under the curve (AUC) with 95% confidence intervals (CIs) and calibration plots were built to evaluate discrimination and calibration. Furthermore, the relationship of mortality with score variables was updated running a multivariate logistic model, and then applied to one thousand bootstrap samples. RESULTS: One hundred and five patients treated for rAAA (97 males, 92.4%) were included in the study (77 ± 8.5 years). An endovascular repair (rEVAR) was performed in 35 patients (3 women, 80 ± 9.0 years) while an open repair (rOAR) in 70 patients (5 women, 75 ± 8.0 years). The 30-day mortality rate was 31.4%, (33/105), 25.7% (9/35), and 34.3% (24/70) for rEVAR and rOAR, respectively (p 0.5). Eight patients (7.6%) were on therapy with warfarin at the time of admission. AUC for tHRS was 0.56 while AUC for mHRS was 0.68 (DeLong test = 0.29). The tHRS' calibration showed underestimation for patients with predicted mortality <25% and overestimation for the remaining; for mHRS, the predictions were well calibrated for patients with estimated mortality <40% with overprediction afterward. The model update demonstrated that the wider effects are due to the interaction between the HRS factors. CONCLUSIONS: tHRS and mHRS showed limited prediction capability with 30-day mortality overestimation in an external validation, raising many concerns about their extended and systematic application. Interaction between factors should be taken into account to enhance the score's performance, especially in high risk patients.
引用
- Frola E, Mortola L, Barili F, et al. External Validation of Traditional and Modified Harborview Risk Scores for Ruptured Abdominal Aortic Aneurysm 30-day Mortality Prediction. Ann Vasc Surg. 2024. PMID: 39341561. doi:10.1016/j.avsg.2024.07.113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。